In:
Reviews in the Neurosciences, Walter de Gruyter GmbH, Vol. 29, No. 3 ( 2018-03-28), p. 241-260
Abstract:
Alzheimer’s disease (AD) is one of the most common neurodegenerative disorders mainly affecting elderly people. It is characterized by progressive loss of memory and cognitive function. More than 95% of AD cases are related to sporadic or late-onset AD (LOAD). The etiology of LOAD is still unclear. It has been reported that environmental factors and epigenetic alterations play a significant role in AD pathogenesis. Furthermore, recently, genome-wide association studies (GWAS) identified 10 novel risk genes: ABCA7 , APOE , BIN1 , CD2AP , CD33 , CLU , CR1 , MS4A6A , MS4A4E , and PICALM , which play an important role for LOAD. In this review, the therapeutic approaches of AD by epigenetic modifications have been discussed. Nowadays, HDAC inhibitors have clinically proven its activity for epigenetic modifications. Furthermore, we try to establish the relationship between HDAC inhibitors and above mentioned LOAD risk genes. Finally, we are hoping that this review may open new area of research for AD treatment.
Type of Medium:
Online Resource
ISSN:
2191-0200
,
0334-1763
DOI:
10.1515/revneuro-2017-0049
Language:
Unknown
Publisher:
Walter de Gruyter GmbH
Publication Date:
2018
detail.hit.zdb_id:
2598365-9
